Dr. Christina S. Baik
Claim this profileFred Hutchinson Cancer Research Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
10 reported clinical trials
18 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
Stage III
EGFR positive
2Lung Cancer
Stage IV
Stage III
EGFR positive
Affiliated Hospitals
Clinical Trials Christina S. Baik is currently running
NVL-655
for NSCLC
This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.
Recruiting1 award Phase 1 & 27 criteria
Repotrectinib
for Solid Tumors
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Recruiting1 award Phase 1 & 27 criteria
More about Christina S. Baik
Clinical Trial Related5 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Christina S. Baik has experience with
- Pembrolizumab
- Ramucirumab
- TPX-0046
- NVL-655
- Atezolizumab
- Durvalumab
Breakdown of trials Christina S. Baik has run
Non-Small Cell Lung Cancer
Lung Cancer
Tumors
Metastatic Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christina S. Baik specialize in?
Christina S. Baik focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Christina S. Baik currently recruiting for clinical trials?
Yes, Christina S. Baik is currently recruiting for 5 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Christina S. Baik has studied deeply?
Yes, Christina S. Baik has studied treatments such as Pembrolizumab, Ramucirumab, TPX-0046.
What is the best way to schedule an appointment with Christina S. Baik?
Apply for one of the trials that Christina S. Baik is conducting.
What is the office address of Christina S. Baik?
The office of Christina S. Baik is located at: Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutchinson Cancer Research Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.